AIA Group Ltd Has $365,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

AIA Group Ltd trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,109 shares of the medical equipment provider’s stock after selling 322 shares during the period. AIA Group Ltd’s holdings in Hologic were worth $365,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Hologic by 5.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after purchasing an additional 1,631 shares in the last quarter. LSV Asset Management grew its stake in Hologic by 307.5% in the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares in the last quarter. Raymond James Trust N.A. grew its stake in Hologic by 7.4% in the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Hologic by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after purchasing an additional 106,315 shares in the last quarter. Finally, Aviva PLC grew its stake in Hologic by 0.7% in the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after purchasing an additional 513 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 in the last quarter. Corporate insiders own 1.75% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $75.38 on Friday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The stock has a market capitalization of $17.69 billion, a PE ratio of 35.73, a P/E/G ratio of 2.54 and a beta of 1.00. The stock has a 50-day simple moving average of $75.75 and a 200 day simple moving average of $72.54.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.07 EPS. Research analysts anticipate that Hologic, Inc. will post 4.01 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of recent research reports. Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Raymond James upped their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. UBS Group upped their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.